R42

WiseWorks is a meeting automation platform helping corporate governance professionals reduce the time they spend on costly tasks.

Spirea Ltd. operates as a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.

Stamp Free operates as a digital postage stamp company that provides postage solutions. The company provides an app that allows personal and business customers to buy stamps or digital postage directly on their mobile phones and then post their letters or parcels in the normal way.

InhibOx is a pioneer in the development and application of new technologies to drive drug discovery. Their multidisciplinary research team has brought together breakthroughs in computational chemistry, cheminformatics, mathematics, cloud computing and software-as-a-service (SaaS) delivery methods to create DrugFinder: the next generation drug discovery platform.

They develop sensor technology to save the lives of first responders by allowing them to safely view hazardous environments remotely and at low cost.

ExSeed Health Test and improve the quality of your sperm from the comfort of your home with thier smartphone device and intelligent lifestyle app.

Celeris Therapeutics is an AI-first drug discovery company that develops proximity-inducing compounds (PICs), focusing on PIC degraders for diseases with high unmet medical needs, such as Parkinson's and various types of cancers. Celeris Therapeutics has developed the Celeris One platform to streamline the development of degraders and, most importantly, rationalize their design. Celeris One leverages structure-based geometric deep learning to prioritize specific E3 ligases, design linkers, and select the most active compounds for synthesis. An in-house automated lab quickly generates experimental data for additional optimization cycles. Celeris Therapeutics collaborates with pharma and biotech companies to jointly discover and develop small-molecule degrader medicines for all therapeutic areas. It is also developing an in-house drug pipeline. Celeris Therapeutics has offices in Menlo Park, CA, and Graz, Austria.

Fountain Therapeutics is discovering and developing treatments for aging-associated diseases. Fountain Therapeutics was founded with the belief that a future in which we live healthier lives longer is more desirable than one in which the company continues to be afflicted by the disease of aging. The company builds a transformative model of aging that re-creates many of the complex hallmark features of aging but in a laboratory dish. We are combining this powerful cellular model with the latest in artificial intelligence and computer vision to develop a disruptive unbiased platform for the identification of novel targets and potential therapeutics.

VividQ is bringing about a revolution in digital display and creating the human-machine interface for the next generation of consumer devices. VividQ's computational display technology is creating a future where 3D holographic images are cast into our everyday environment, removing the screens that separate our real and virtual experiences. The company partners with leading original electronics manufacturers (OEMs) to integrate its advanced software and hardware solutions into augmented reality (AR), virtual reality (VR), automotive head-up displays, and other consumer electronics. Founded in 2017, the company is based in Cambridge, U.K., with partners and teams in the U.S. and Japan.

Abselion is the biological sensor for rapid and cost-effective detection of biological substances like proteins, DNA, or small molecules.

Concr is a mission-driven techbio company that uses established methods from astrophysics to accurately predict patient outcomes and treatment response to novel and existing cancer therapies. Our unique approach allows iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, removing the need for ‘big data’ and yielding most accurate multi-modal tumour models. Concr’s cloud native platform – FarrSight® – empowers researchers to computationally simulate clinical trials, make advanced predictions about therapeutic response and biomarkers, and perform standard bioinformatics analyses directly. Concr is headquartered in London, with a wholly-owned subsidiary in Brisbane, Australia. The company is a venture capital-backed enterprise, with investors including the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Debiopharm, Cambridge Angels, Deep Science Ventures and SyndicateRoom.

Celeris Therapeutics is an AI-first drug discovery company that develops proximity-inducing compounds (PICs), focusing on PIC degraders for diseases with high unmet medical needs, such as Parkinson's and various types of cancers. Celeris Therapeutics has developed the Celeris One platform to streamline the development of degraders and, most importantly, rationalize their design. Celeris One leverages structure-based geometric deep learning to prioritize specific E3 ligases, design linkers, and select the most active compounds for synthesis. An in-house automated lab quickly generates experimental data for additional optimization cycles. Celeris Therapeutics collaborates with pharma and biotech companies to jointly discover and develop small-molecule degrader medicines for all therapeutic areas. It is also developing an in-house drug pipeline. Celeris Therapeutics has offices in Menlo Park, CA, and Graz, Austria.

Stamp Free operates as a digital postage stamp company that provides postage solutions. The company provides an app that allows personal and business customers to buy stamps or digital postage directly on their mobile phones and then post their letters or parcels in the normal way.

Senisca is a biotech start-up. They propose to create a new generation of oligonucleotide-based interventions to rewind the clock in old cells and target diseases and cosmetic signs of aging. They provide molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence.

Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well as safe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.